How to Buy Arcutis Biotherapeutics Stock
Arcutis Biotherapeutics Inc
Arcutis Biotherapeutics, Inc. is a biopharmaceutical firm dedicated to developing and marketing therapies for a range of skin-related diseases.
Arcutis Biotherapeutics stock last closed at $24.38, down 0.85% from the previous day, and has increased 80.59% in one year. It has overperformed other stocks in the Biotechnology industry by 1.54 percentage points. Arcutis Biotherapeutics stock is currently +87.97% from its 52-week low of $12.97, and -23.26% from its 52-week high of $31.77.
At the moment, there are 125.08M ARQT shares outstanding. The market value of ARQT is $3.05B. In the last 24 hours, 1.31M ARQT shares were traded.
How to Buy Arcutis Biotherapeutics Stock
Not sure how to invest in Arcutis Biotherapeutics stock? Here's how.
- Choose where to buy Arcutis Biotherapeutics stock: You need to pick a stock brokerage, but don't worry - we've tested dozens of stock brokerages and apps to help you choose where to buy Arcutis Biotherapeutics stock.
- Open your brokerage account: Sign up for 0% fee trading with the highest-rated brokerage we've selected.
- Deposit money your investment account: Select your method of payment and add your details.
- Analyze Arcutis Biotherapeutics stock: The Arcutis Biotherapeutics ticker symbol is ARQT. Is Arcutis Biotherapeutics stock a good investment? Should you buy shares of ARQT? How do ARQT's underlying business fundamentals look? Do top analysts think Arcutis Biotherapeutics is a good buy? Why has ARQT's stock price moved recently? (Hint: Our stock market analysis website can help you figure out if ARQT is a good stock to buy).
- Place your ARQT trade: Decide if you will purchase ARQT shares at the current market price or use a limit order to purchase ARQT shares at a specific price.
- Watch your investment in ARQT: Create a watchlist to monitor your new investment in Arcutis Biotherapeutics stock.
Step 1: Choose where to buy Arcutis Biotherapeutics stock
You need a brokerage account in order to access the NASDAQ market and buy ARQT stock.
Our recommended brokerage: eToro
We believe that eToro is the best stock brokerage. eToro gives you:
- Invest in stocks with 0% commissions: Invest without paying trading commissions.
- Buy fractional shares: Even if you don't have the money to buy a full share, you can still buy the stock.
- Access to global financial markets: From Tech to Energy, New York to London (for US users, only US stocks are available) — you can fill your portfolio with stocks from the globe's top exchanges.
- Social investing: eToro boasts a community of more than 20 million users worldwide. Talk to, learn from, and copy the unique crypto portfolios of top investors.
- Security: eToro is a regulated and licensed brokerage platform.
- Buy other financial assets: Such as ETFs and cryptos.
Get $10 towards your purchase of shares by creating an account with eToro today. This offer is only for US users.
Open eToro AccountStep 2: Open your brokerage account
Now that you've chosen the best brokerage, the next step is to fill out some personal info so you can invest in ARQT today.
How to Start a New Brokerage Account on eToro
- Click here to get started.eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
- Input your personal data to open a new trading account.
- Submit your information by pressing the "Create Account" button. Get started with eToro today
Step 3: Deposit money your investment account
Now that you have filled out your info on the best stock market app for beginners, you need to deposit funds:
Check out this video walkthrough to see the process of depositing funds into your brokerage account.
Step 4: Analyze Arcutis Biotherapeutics stock
After you have identified the best place to buy Arcutis Biotherapeutics stock, it's very important to evaluate their stock prior to investing, so you truly comprehend the risk and opportunity.
Arcutis Biotherapeutics stock data
Arcutis Biotherapeutics Overview
WallStreetZen was designed to help average investors perform more accurate fundamental analysis in minutes instead of hours.
You can see all of the due diligence checks on ARQT's stock page.
Is ARQT stock overvalued?
Analysts use a variety of different financial metrics, analyses, models, and charts to gauge ARQT's true value.
Using relative valuations methods:
- ARQT may be overvalued based on its P/B ratio of 16.08x, relative to Biotechnology industry P/B ratio of 4.85x
You can do additional valuation analysis on ARQT's stock here.
How do ARQT Financials look?
Positive Health Checks:
- ARQT profit margin has gone up from -61% to -0.6% in the past year.
- There are more short-term assets than long-term liabilities on the ARQT balance sheet.
- ARQT's operating cash flow of $26.99M allows it to safely service it's debt of $114.67M.
- There are more short-term assets than short-term liabilities on the ARQT balance sheet.
Negative Health Checks:
- Total ARQT debt is higher than 5 years ago, relative to shareholder equity.
- ARQT has a relatively high debt to equity ratio of 1.43.
- ARQT earnings of $12.08M is not sufficient to cover its interest payments.
Is it a good time to buy ARQT stock, according to analysts?
Out of 5 sell side analysts who track ARQT, the consensus analyst rating on Arcutis Biotherapeutics is a Strong Buy
It's important to keep in mind that analyst forecasts are not stock recommendations, nor are they financial advice.
You can dig deeper into what analysts are saying on the Arcutis Biotherapeutics stock forecast page.
Metrics for Advanced ARQT Traders
ARQT Earnings
Last year, ARQT revenue was $415.62M. In the last 3 year, ARQT's revenue has gone up by 398.47% per year. This was faster than the Biotechnology industry average of 32.07%.
You can research ARQT's earnings and revenue performance here.
What are ARQT insiders up to?
In the last 12 months, executives and large shareholders at ARQT have sold more shares than they have bought.
Patrick Burnett, Reporting Persons Title EVP Chief Medical Officer of ARQT, was the latest ARQT insider to sell. They sold $4,673.10 worth of ARQT shares on May 11, 2026.
Get more info about who owns ARQT stock here.
Can I get consistent income from ARQT stock?
No, Arcutis Biotherapeutics doesn't provide an income stream by paying out dividends.
Get opinions from other traders
One of the major reasons eToro is our top-rated brokerage is because of its social trading community.
Click below to learn what other traders have to say.
Step 5: Place your ARQT trade
You have two main options:
- Market order: A market order is an order to buy or sell a security at the best possible price.
Market orders are usually fine. - Limit order: A limit order lets you buy or sell a stock at a specific price (or better).
If you want to be sure you're buying or selling at an exact dollar amount limit, place a limit order.
Press the Open Trade button and eToro will place the order.
If you require additional assistance investing in stocks on eToro, click the how to video below:
Step 6: Watch your investment in ARQT
Now that you own some shares in ARQT, you'll want to keep up with your company.
Start a watchlist to track the most important metrics related to your ARQT stock.
ARQT Feed
How to Buy Stock in Arcutis Biotherapeutics
To reiterate, here are the 6 steps you need to take to buy Arcutis Biotherapeutics stock right now:
- Choose where to buy Arcutis Biotherapeutics stock
- Open your brokerage account
- Deposit money your investment account
- Analyze Arcutis Biotherapeutics stock
- Place your ARQT trade
- Watch your investment in ARQT
If you require a online brokerage, eToro is our recommended option.
Get Started with eToro TodayIf you would like to track your new investment in Arcutis Biotherapeutics, hit the button below to create your watchlist.
Trending Articles
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.